European Commission

• Strategy for Europe – European Commission strategy (2020)Reform of the EU’s Pharma legislation Driving innovation for a competitive pharmaceutical industry – European Commission Evaluation Report (2023)
• Potential measures to facilitate the productions of active pharmaceutical ingredients (APIs) – European Commission Evaluation Report (2023)
• Roadmap/Inception impact assessment for the revision of the general pharmaceutical legislation – European Commission Roadmap (2021)
• Study on medicines shortages – European Commission Report (2021)
• Study on optimising public procurement of medicines  – European Commission Report (2022)
• Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation – European Commission Report (2023)
• Bio-based value chains for chemicals, plastics and pharmaceuticals: A comparison of bio-based and fossil-based value chains – European Commission Report (2021)
• Update on progress and implementation: European Union strategic approach to pharmaceuticals in the environment – European Commission Evaluation Report (2021)
• Future-proofing pharmaceutical legislation: Study on medicine shortages : country fiches – European Commission Report (2022)
• Options for a strategic approach to pharmaceuticals in the environment – European Commission Report (2022)
• European pharmaceutical research and development: Could public infrastructure overcome market failures? – European Commission Report (2021)
• Trade in counterfeit pharmaceutical products – European Commission Report (2020)
• Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector – European Commission Report (2020)
• Medicine shortage in the EU during the novel coronavirus outbreak – European Commission Report (2020)
• Artificial intelligence in medicine and healthcare: Applications, availability and societal impact – European Commission Report (2020)
• EU Legislation on the Pharmaceutical Sector – EudraLex, EU Legislation (2023)

European Parliament

• European Parliament resolution of 17 September 2020 on a strategic approach  to pharmaceuticals in the environment (2019/2816(RSP)) - European Parliament Resolution (2020)

• A Pharmaceutical Strategy for Europe INI – ENVI article (2021)
• Resolution on a pharmaceutical strategy for Europe (2021/2013(INI)) - European Parliament resolution (24 November 2021)

• Opinion on a pharmaceutical strategy for Europe – European Parliament JURI Opinion (2021)

• Opinion a pharmaceutical strategy for Europe – European Parliament ITRE Opinion (2021)
• Opinion on a pharmaceutical strategy for Europe – European Parliament ENVI Opinion (2021)
• Opinion on "Shortage of medicines: how to address an emerging problem" – European Parliament JURI Opinion (2020)
• Opinion on "Shortage of medicines: how to address an emerging problem" – European Parliament ITRE Opinion (2020)
• Opinion on "Shortage of medicines: how to address an emerging problem" – European Parliament DEVE Opinion (2020)
• Opinion on "Shortage of medicines: how to address an emerging problem" – European Parliament INTA Opinion (2020)
• Opinion on "Shortage of medicines: how to address an emerging problem" – European Parliament TRAN Opinion (2020)
• Opinion on "Shortage of medicines: how to address an emerging problem" – European Parliament ENVI Opinion (2020)

Council of the European Union

• European Medicines Agency: Council agrees approach on a more modern and simplified fee structure – Council of the European Union Press Release (2023)
• Council adopts law on the emergency framework regarding medical countermeasures – Council of the European Union Press Release (2022)
• EU adopts measures in support of generic pharmaceuticals producers – Council of the European Union Press Release (2019)
• The EU’s emergency response to the COVID-19 pandemic – Council of the European Union Infographic (2021)
• Council takes action to mitigate risk of medical devices shortage – Council of the European Union Press Release (2023)
• Health Technology Assessment: Council agrees its negotiating position – Council of the European Union Press Release (2021)
• An international agreement on pandemic prevention and preparedness – Council of the European Union Policy Summary (2023)
• The EU's response to the COVID-19 pandemic – Council of the European Union Policy Summary (2023)
• European Health Union: protecting Europeans against cross-border health threats – Council of the European Union Policy Summary (2023)
• Health technology assessment – Council of the European Union Policy Summary (2023)
• EU health policy – Council of the European Union Policy Summary (2023)

Additional Articles, Studies and Reports

• Pharmaceutical industry - European Medicines Agency Infopage (2023)

•  The European Medicines Agency’s contribution to science, medicines and health in 2022 – European Medical Agency Annual Report (2022)
• Pharmaceutical industry in Europe - Statista fact sheets (2023)
• The Pharmaceutical Industry in Figures – European Federation of Pharmaceutical Industries and Associations Report (2022)
• Let’s discuss the future of Unmet Medical Needs (UMN) in EU Policies – European Federation of Pharmaceutical Industries and Associations Report (2023)
• A value-based approach to pricing – European Federation of Pharmaceutical Industries and Associations Position Paper (2023)
• Factors affecting the location of biopharmaceutical investments and implications for European policy priorities – Chales River Associates Final Report (2022)
• EFPIA Position Paper on EMA Fees – European Federation of Pharmaceutical Industries and Associations Position Paper (2022)
• OECD Pharmaceuticals – OECD Health Policies and Data (2023)
• New regulatory strategies to manage medicines shortages in Europe – Musazzi et al., International Journal of Pharmaceutics, Volume 579, (2020)
• Role of innovation in pharmaceutical regulation: A proposal for principles to evaluate EU General Pharmaceutical Legislation from the innovator perspective - Heikkinen et al., Drug Discovery Today, Volume 28, Issue 5, (2023)
• Strategic purchasing and health systems resilience: Lessons from COVID-19 in selected European countries – Montas et al., Health Policy, Volume 126, Issue 9, (2022)

• Phasing out of extraordinary COVID-19 regulatory flexibilities - European Medicines Agency article (2023)
• Use of real-world evidence in regulatory decision making - European Medicines Agency article (2023)
• Report: How EU ensured safety of medicines during COVID-19 - European Medicines Agency article (2023)
• What the EU must consider as it enacts its Global Health Strategy – Euractiv article (2022)
• EU parliament moves closer to agreeing Medicines Agency’s fee system – Euractiv article (2023)
• Solving the issue of medicine shortages in the EU – Euractiv article (2023)
• The EU butts heads with Big Pharma to make medicines cheaper – Politico article (2023)
• EU capitals propose Chips Act for medicines – Politico article (2023)
• The real reason Europe’s medicines industry is dying – Politico article (2023)
• Pharma reform: Patients can’t afford to wait. Act now. – Politico article (2023)